Open access
Open access
Powered by Google Translator Translator

Covid-19

Italian lab study finds Sputnik V beat Pfizer’s mRNA vaccine against Omicron – yielding higher antibody levels.

27 Jan, 2022 | 09:47h | UTC

Italian Lab Study Finds Sputnik V Beat Pfizer’s mRNA Vaccine Against Omicron – Yielding Higher Antibody Levels – Health Policy Watch

 

RCT: Heterologous (Pfizer, J&J, or AstraZeneca) vs. homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil.

26 Jan, 2022 | 02:30h | UTC

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study – The Lancet

Commentaries:

Boosting immunity after CoronaVac – The Lancet

Covid-19: CoronaVac immunity is strongest after boosting with a different vaccine – The BMJ

Related Study: Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination – Nature Medicine

 

Commentary on Twitter

 

As Pfizer and BioNTech begin a clinical trial of Omicron-based vaccine, the timeline to authorization is unclear.

26 Jan, 2022 | 02:20h | UTC

As Pfizer and BioNTech begin clinical trial of Omicron-based vaccine, timeline to authorization is unclear – STAT

See also:

Pfizer begins testing omicron-matched COVID shots in adults – Associated Press

Pfizer and BioNTech start trials of new Omicron-specific jab – BBC

Pfizer and BioNTech begin testing an omicron-specific COVID-19 vaccine – NPR

 

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

26 Jan, 2022 | 02:23h | UTC

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 – JAMA

Commentary: COVID 19: Risk of Myocarditis Highest Following Second Vaccine Dose Among Adolescent and Young Adult Males – MedicalResearch.com

Related:

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Cohort study: Among patients who survived ICU treatment for COVID-19, 75% still reported physical, mental, or cognitive symptoms after 1 year.

26 Jan, 2022 | 02:28h | UTC

Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19 – JAMA

Commentaries:

75% of COVID ICU survivors have physical symptoms 1 year on – CIDRAP

Majority of COVID-19 survivors experience health problems one-year post ICU admission – News Medical

 

Deltacron: the story of the variant that wasn’t.

26 Jan, 2022 | 02:19h | UTC

Deltacron: the story of the variant that wasn’t – Nature

 

Opinion: Preventing SARS-CoV-2 transmission in health care settings in the context of the Omicron variant.

26 Jan, 2022 | 02:14h | UTC

Preventing SARS-CoV-2 Transmission in Health Care Settings in the Context of the Omicron Variant – JAMA

 

Commentary on Twitter

 

[Preprint] High prevalence of olfactory disorders 18 months after contracting COVID-19.

26 Jan, 2022 | 02:11h | UTC

High prevalence of olfactory disorders 18 months after contracting COVID-19 – medRxiv

Commentaries:

Half of first-wave Covid cases may have lasting harm to sense of smell – The Guardian

Prevalence of olfactory dysfunction 18 months after SARS-CoV-2 infection – News Medical

 

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

25 Jan, 2022 | 09:50h | UTC

Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial – JAMA

Editorial: Defining Optimal Respiratory Support for Patients With COVID-19 – JAMA

 

Commentary on Twitter

 

ACP living, rapid review: risk for reinfection after SARS-CoV-2.

25 Jan, 2022 | 09:47h | UTC

Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection – Annals of Internal Medicine

 

Commentary on Twitter

 

New CPR guidance addresses more contagious COVID-19 variants amidst evolving pandemic.

25 Jan, 2022 | 09:48h | UTC

News release: New CPR guidance addresses more contagious COVID-19 variants amidst evolving pandemic – American Heart Association

See Guidance: 2022 Interim Guidance to Healthcare Providers for Basic and Advanced Cardiac Life Support in Adults, Children, and Neonates with Suspected or Confirmed COVID-19: From the Emergency Cardiovascular Care Committee and Get With the Guidelines®-Resuscitation Adult and Pediatric Task Forces of the American Heart Association in Collaboration with the American Academy of Pediatrics, American Association for Respiratory Care, The Society of Critical Care Anesthesiologists, and American Society of Anesthesiologists

 

WHO drops opposition to boosters – recommends third Pfizer jab for adults & two vaccines for children ages 5 & up.

25 Jan, 2022 | 09:45h | UTC

WHO Drops Opposition to Boosters – Recommends Third Pfizer Jab for Adults & Two Vaccines for Children Ages 5 & Up – Health Policy Watch

Related:

WHO updated roadmap for prioritizing uses of COVID-19 vaccines.

WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids.

 

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

25 Jan, 2022 | 09:43h | UTC

Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case–Control Study – Annals of Internal Medicine

News release: BNT162b2 COVID-19 vaccine associated with increased risk of carditis – American College of Physicians

Related:

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa.

25 Jan, 2022 | 09:41h | UTC

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study – The Lancet

Commentary: Omicron severity: milder but not mild – The Lancet

 

Commentary on Twitter

 

COVID-19: endemic doesn’t mean harmless.

25 Jan, 2022 | 09:36h | UTC

COVID-19: endemic doesn’t mean harmless – Nature

 

[Preprint] Cohort study: Reduced risk of hospitalization associated with infection with SARS-CoV-2 Omicron relative to Delta.

25 Jan, 2022 | 09:40h | UTC

Reduced Risk of Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish Cohort Study – SSRN / Preprints with The Lancet

Commentaries:

Danish report: lower risk of hospitalisation with Omicron – Copenhagen Post

Omicron has a 36% lower risk for hospitalization compared to Delta: Denmark study – Outbreak News Today

 

Commentary on Twitter

 

We will be living with COVID for foreseeable future; but we can end acute phase of pandemic this year — WHO Director General.

25 Jan, 2022 | 09:34h | UTC

We Will be Living with COVID for Foreseeable Future; but We Can End Acute Phase of Pandemic this Year — WHO Director General – Health Policy Watch

 

[Preprint] Omicron SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta.

25 Jan, 2022 | 09:37h | UTC

Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2) – medRxiv

 

Commentary on Twitter

 

European CDC on Omicron: “among Omicron cases reported to TESSy, 1.14% were hospitalised, 0.16% required ICU admission/respiratory support, and 0.06% died”.

24 Jan, 2022 | 08:54h | UTC

Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 20 January 2022) EU/EEA – European Centre for Disease Prevention and Control (ECDC)

 

Case-control study: 3 doses of mRNA vaccines were associated with reduced infections with SARS-CoV-2 Omicron and Delta variants compared to no vaccination or 2 doses.

24 Jan, 2022 | 08:56h | UTC

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants – JAMA

Editorial: Booster Vaccination to Prevent COVID-19 in the Era of Omicron: An Effective Part of a Layered Public Health Approach – JAMA

Commentaries: New data show booster doses protect against Omicron – CIDRAP

Boosters provide the best protection against Omicron variant, CDC studies show, raising new questions about what it means to be fully vaccinated – CNN

Related CDC Studies:

COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 – CDC Morbidity and Mortality Weekly Report

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 – CDC Morbidity and Mortality Weekly Report

 

Commentary on Twitter

 

WHO updated roadmap for prioritizing uses of COVID-19 vaccines.

24 Jan, 2022 | 08:49h | UTC

WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines – World Health Organization

Commentary: WHO: COVID boosters should start with most vulnerable – Associated Press

 

Commentary on Twitter (thread – click for more)

 

WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids.

24 Jan, 2022 | 08:35h | UTC

WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids – CIDRAP

See also: Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing – World Health Organization

 

Updated Guideline: Recommended drugs and biologics in adult patients with COVID-19.

24 Jan, 2022 | 08:52h | UTC

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 – Covid-19 Advisory for Ontario

 

Commentary on Twitter (thread – click for more)

 

WHO Technical Brief: Enhancing response to Omicron SARS-CoV-2 variant.

24 Jan, 2022 | 08:36h | UTC

Enhancing response to Omicron SARS-CoV-2 variant – World Health Organization

 

A guide to immunotherapy for COVID-19.

24 Jan, 2022 | 08:29h | UTC

A guide to immunotherapy for COVID-19 – Nature Medicine

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.